Connect with us

Bloomberg Technology

Novavax Could Deliver 100M Covid-19 Vaccine Doses By End of Year, Says R&D Head

May.14 — Novavax Inc.’s vaccine is one of at least 100 potential candidates trying to curb the spread of the virus that causes Covid-19. The biotech company recently received a funding of $388-million from the Coalition for Epidemic Preparedness Innovation, making it the biggest investment ever from the group. Dr. Gregory Glenn, Novavax’s president of…

Published

on

May.14 — Novavax Inc.’s vaccine is one of at least 100 potential candidates trying to curb the spread of the virus that causes Covid-19. The biotech company recently received a funding of $388-million from the Coalition for Epidemic Preparedness Innovation, making it the biggest investment ever from the group. Dr. Gregory Glenn, Novavax’s president of research and development, speaks on “Bloomberg Technology.”

Continue Reading
Advertisement
12 Comments

12 Comments

  1. 270360 270360

    May 14, 2020 at 11:39 pm

    The good Novavax Inc.s will help humanity and here is some interesting , (here is kid’s opinion). God bless our leaders for taking care of us all!

  2. Altamash

    May 15, 2020 at 12:26 am

    Is it potential vaccine or actually curable?

  3. Dhiraj khatri

    May 15, 2020 at 2:04 am

    nice

  4. Voltaire

    May 15, 2020 at 2:19 am

    But will it be approved by the end of the year?

  5. carlos blandino

    May 15, 2020 at 3:12 am

    I bought this company for $20 a share 3 days ago. It already went up to $40 s share. Thanks Novavak for making me money.

    • Cao Minh Duc

      May 17, 2020 at 3:26 am

      It’s not Novavax that made you the money, it’s the senseless stock speculators that gave you that money. Vaccine development is an extremely unpredictable process. Far more failures than successes. Yet we have seen biotech companies that double, triple in value since they release several “news” on their Covid 19 related vaccine works.

  6. Michael Weinberg

    May 15, 2020 at 3:57 am

    There is NO need for a COVID vaccine. Here is Proof presented before US The Senate that IV Vitamin C in cocktail is HIghly successful in SAFELY treating COVID 19: @. YES SAFELY!

    • ajay g

      May 15, 2020 at 9:33 am

      What?

    • Mothra J Disco

      May 15, 2020 at 9:43 am

      ajay g Pseudoscience people just ignore

      Same people who think B-17 is a cure for cancer

  7. Joe Bloe

    May 15, 2020 at 5:36 am

    How about some transparency from Emily Chang — like who’s paying you to trash Tesla, what started your hatred rampage against men, and when are you going to learn how to dress like a woman instead of an awkward teenager?

    • hmad_wesk 99

      May 15, 2020 at 7:23 am

      When will you stop peeing in your own pants?????

  8. Rosa G. The Truth Hurtz

    May 17, 2020 at 1:22 am

    These assholes are making billions while striping away civil liberties smh

Leave a Reply

Your email address will not be published. Required fields are marked *

Bloomberg Technology

Crusoe CEO: Data Center Indusry Has a ‘Marketing Issue’

Crusoe CEO Chase Lochmiller discusses the AI infrastructure company’s nearly $4 billion in fresh funding sending its valuation to almost $31 billion. He also discusses how it will fuel the company’s push to build AI infrastructure spanning data centers, cloud computing and managed AI services. He says Crusoe could eventually enter the public markets and…

Published

on

Crusoe CEO Chase Lochmiller discusses the AI infrastructure company’s nearly $4 billion in fresh funding sending its valuation to almost $31 billion. He also discusses how it will fuel the company’s push to build AI infrastructure spanning data centers, cloud computing and managed AI services. He says Crusoe could eventually enter the public markets and pushes back against growing opposition to data centers, arguing the industry has a “marketing issue” and needs to better communicate its impact on water, jobs and local tax revenue. He joins Ed Ludlow on “Bloomberg Tech.”
——–
Like this video? Subscribe to Bloomberg Tech on YouTube:

 
Watch the latest full episodes of “Bloomberg Tech” with Ed Ludlow here:

 
Get the latest in tech from Silicon Valley and around the world here:

Connect with us on…
X:
Facebook:
Instagram:
 
Follow Ed Ludlow on X here:
 
Listen to the daily Bloomberg Tech podcast here:

 
More from Bloomberg Business
Connect with us on…
X:
Facebook:
Instagram:
LinkedIn:
TikTok:

Continue Reading

Bloomberg Technology

Former FTC Technologist Warns Against an AI ‘Cartel’

As frontier AI labs seek greater coordination on safety, Neil Chilson, Head of AI Policy at the Abundance Institute and former FTC Chief Technologist, warns that government-backed antitrust exemptions could create a durable “cartel” that ultimately harms competition. He argues companies can collaborate on safety standards without suspending antitrust rules, and that existing consumer-protection and…

Published

on

As frontier AI labs seek greater coordination on safety, Neil Chilson, Head of AI Policy at the Abundance Institute and former FTC Chief Technologist, warns that government-backed antitrust exemptions could create a durable “cartel” that ultimately harms competition. He argues companies can collaborate on safety standards without suspending antitrust rules, and that existing consumer-protection and liability laws already provide tools for addressing harms caused by AI. He joins Ed Ludlow on “Bloomberg Tech.”
——–
Like this video? Subscribe to Bloomberg Tech on YouTube:

 
Watch the latest full episodes of “Bloomberg Tech” with Ed Ludlow here:

 
Get the latest in tech from Silicon Valley and around the world here:

Connect with us on…
X:
Facebook:
Instagram:
 
Follow Ed Ludlow on X here:
 
Listen to the daily Bloomberg Tech podcast here:

 
More from Bloomberg Business
Connect with us on…
X:
Facebook:
Instagram:
LinkedIn:
TikTok:

Continue Reading

Bloomberg Technology

Anthropic Investor Franklin: AI Safety Concerns Won’t Slow Spending

Calls to “pace” development at the AI frontier are unlikely to translate into a slowdown in infrastructure spending, according to Sara Araghi, Franklin Templeton Portfolio Manager and Franklin Venture Partner. She argues that even if labs temper some model training, growing inference demand will continue to require enormous amounts of compute. Araghi also discusses why…

Published

on

Calls to “pace” development at the AI frontier are unlikely to translate into a slowdown in infrastructure spending, according to Sara Araghi, Franklin Templeton Portfolio Manager and Franklin Venture Partner. She argues that even if labs temper some model training, growing inference demand will continue to require enormous amounts of compute. Araghi also discusses why heightened AI safety concerns could boost demand for cybersecurity and why she doesn’t expect the debate to derail funding or anticipated AI IPOs. She joins Ed Ludlow on “Bloomberg Tech.”
——–
Like this video? Subscribe to Bloomberg Tech on YouTube:

 
Watch the latest full episodes of “Bloomberg Tech” with Ed Ludlow here:

 
Get the latest in tech from Silicon Valley and around the world here:

Connect with us on…
X:
Facebook:
Instagram:
 
Follow Ed Ludlow on X here:
 
Listen to the daily Bloomberg Tech podcast here:

 
More from Bloomberg Business
Connect with us on…
X:
Facebook:
Instagram:
LinkedIn:
TikTok:

Continue Reading

Trending